Owkin
Elodie Pronier is an accomplished professional in the fields of biomedical discovery and oncology research. Currently serving as Head of Biomedical Discovery at Owkin since April 2019, Elodie has held various roles, including Co-Director of Biomarker and Target ID and Lead Biologist-Preclinical Program Leader, where responsibilities include leading biological validation pipelines, managing mesothelioma projects, and enhancing collaboration with CROs and academic partners. Prior experience includes a significant tenure at Memorial Sloan Kettering Cancer Center, where Elodie was a Scientist/Project Leader and engaged in national and international collaborations, and at Institut Gustave Roussy as a PhD student managing research on TET2 functions. Elodie's education includes a PhD in Oncology and Hematology from Université Paris Cité and multiple degrees in Genetics and Biology.
This person is not in any offices
Owkin
6 followers
Owkin believes that medical research should be collaborative, inclusive, and privacy-preserving. Today, Owkin is pioneering AI in healthcare. It leverages its collaborative federated learning software and expert AI capabilities to bring solutions to optimize drug development and improve patient care in oncology. Owkin’s work has been published in Nature Medicine and other top-tier journals. Owkin has raised over $70M from leading VC funds and is now working with the most prominent cancer centers and pharmaceutical companies in Europe and the US. Additionally, Owkin leads several federated learning consortia, including; MELLODDY, to facilitate 'co-opetive' drug discovery between pharma companies, and Healthchain, to allow collaborative research across multiple hospitals. Owkin was co-founded in 2016 by Thomas Clozel, MD, a clinical research doctor and former assistant professor in clinical hematology, and by Gilles Wainrib, Ph.D., an academic pioneer in the field of Artificial Intelligence in biology.